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Preeclampsia (PE) is a complex, multisystem disorder that remains a leading cause of 
morbidity and mortality in pregnancy. Four main classes of dysregulation accompany PE 
and are widely considered to contribute to its severity. These are abnormal trophoblast 
invasion of the placenta, anti-angiogenic responses, oxidative stress, and inflammation. 
What is lacking, however, is an explanation of how these themselves are caused. We 
here develop the unifying idea, and the considerable evidence for it, that the originating 
cause of PE (and of the four classes of dysregulation) is, in fact, microbial infection, that 
most such microbes are dormant and hence resist detection by conventional (replica-
tion-dependent) microbiology, and that by occasional resuscitation and growth it is they 
that are responsible for all the observable sequelae, including the continuing, chronic 
inflammation. In particular, bacterial products such as lipopolysaccharide (LPS), also 
known as endotoxin, are well known as highly inflammagenic and stimulate an innate 
(and possibly trained) immune response that exacerbates the inflammation further. The 
known need of microbes for free iron can explain the iron dysregulation that accompa-
nies PE. We describe the main routes of infection (gut, oral, and urinary tract infection) 
and the regularly observed presence of microbes in placental and other tissues in PE. 
Every known proteomic biomarker of “preeclampsia” that we assessed has, in fact, also 
been shown to be raised in response to infection. An infectious component to PE fulfills 
the Bradford Hill criteria for ascribing a disease to an environmental cause and suggests 
a number of treatments, some of which have, in fact, been shown to be successful. 
PE was classically referred to as endotoxemia or toxemia of pregnancy, and it is ironic 
that it seems that LPS and other microbial endotoxins really are involved. Overall, the 
recognition of an infectious component in the etiology of PE mirrors that for ulcers and 
other diseases that were previously considered to lack one.
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iNTRODUCTiON
Preeclampsia
Preeclampsia is a multisystem disorder of pregnancy, characterized and indeed defined by the pres-
ence of hypertension after 20 weeks’ gestation and before the onset of labor, or postpartum, with 
either proteinuria or any multisystem complication (1–9). It is a common condition, affecting some 
3–5% of nulliparous pregnant women (8, 10) and is characterized by high mortality levels (11–14). 
TAble 1 | Some known risk factors for preeclampsia [based on part in Ref. (3, 7, 18–20)].
Risk factor Comments Selected reference
Nulliparous women Epidemiological observation, suggested biochemical explanations include soluble 
fms-like tyrosine kinase 1 (sFlt1):placental growth factor (PlGF) ratio
(3, 21)
Increased maternal age (especially >35 years) Epidemiological observation, though may be related to existing age-related disease (20, 22–25)
History of preeclampsia in previous pregnancy Epidemiological observation, virtually akin to recurrence; among the strongest factors (18, 26)
Multi-fetal gestation, i.e., twins, etc. Extra demands on mother’s circulation; larger placenta, danger of ischemia? Relative 
risk ~3.5× in nulliparous
(27–29)
Obesity (especially BMI > 35) Can affect blood pressure (BP) directly, also via intra-abdominal pressure; 
diabetogenic and inflammatory; possible role for asymmetric dimethylarginine
(30–33)
Booking diastolic BP > 80 mm Hg An essential part of the later syndrome (19)
Booking proteinuria on at least 1 occasion, or 
≥0.3 g/24 h
An essential part of the later syndrome (19)
Family history of preeclampsia (mother or sister) Twofold to fivefold increase in likelihood. Genetic factors are said to account for 
some 50% of the variance, though few properly controlled monozygotic/dizygotic 
twin studies exist; when done the heritability of PE can be lower to negligible
(34–39)
Pre-existing medical conditions, including chronic 
hypertension, diabetes mellitus, antiphospholipid 
syndrome, thrombophilia, autoimmune disease, renal 
disease, systemic lupus erythematosus, and infertility
These are mainly seen as (other) vascular diseases or comorbidities; however, 
antiphospholipid antibodies (Hughes’ syndrome) are of special interest as they can 
have an infectious origin; one-third of women with them will develop PE, and they 
cause recurrent pregnancy loss
(6, 40–51)
Urinary tract infection (UTI) An infectious origin for PE is the focus here, and not just from UTI (52–54) and see below
See also http://bestpractice.bmj.com/best-practice/monograph/326/diagnosis.html. Note that most of these are risk factors that might and do pre-dispose for other diseases (or are 
themselves diseases).
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There  is no known cure other than delivery, and consequently, 
preeclampsia (PE) also causes significant perinatal morbidity and 
mortality secondary to iatrogenic prematurity. There are a variety 
of known risk factors (Table 1) that may be of use in predicting 
a greater likelihood of developing PE, albeit there are so many, 
with only very modest correlations, that early-stage (especially 
the first-trimester) prediction of late-stage PE remains very dif-
ficult (8, 15–17).
It is striking that most of the “risk factors” of Table 1 are, in 
fact, risk factors for multiple vascular or metabolic diseases, i.e., 
they merely pre-dispose the individual to a greater likelihood of 
manifesting the disease or syndrome (in this case PE). Indeed, 
some of them are diseases. This would be consistent with the 
well-known comorbidities, e.g., between PE and later cardiovas-
cular disease [e.g., Ref. (55–65)], between PE and intracerebral 
hemorrhage during pregnancy [OR 10.39 (66)], and between PE 
and stroke postpartum (67, 68). The penultimate row of Table 1 
lists a series of diseases that amount to comorbidities, although 
our interest was piqued by the observation that one-third of 
patients with antiphospholipid syndrome have PE, and infec-
tious agents with known cross-reacting antigens are certainly 
one original (external) source of the triggers that cause the 
antiphospholipid antibodies (43, 44, 47, 69) (and see below). 
Similarly, in the case of urinary tract infection (UTI), the “risk” 
factor is a genuine external trigger, a point [following the call 
by Mignini and colleagues (70) for systematic reviews] that we 
shall expand on considerably here. [A preprint has been lodged 
at bioRxiv (71).]
In recent decades, intense investigation has led to the devel-
opment of a two-stage etiological model for PE, first proposed 
by Redman (72), in which inadequate remodeling of the spiral 
arteries in early gestation results in poor placental development 
(stage one) and the resultant ischemia/reperfusion injury and 
oxidative stress (73) eventually leads to maternal vascular 
endothelial cell dysfunction and the maternal manifestations of 
the disease (stage 2) (72, 74–77). However, many clinical incon-
sistencies challenge the simplicity of this model. For example, 
while the association between poor placentation and PE is well 
established, it is not specific. Poor placentation and fetal growth 
restriction (FGR) frequently present without maternal signs of 
PE. Moreover, FGR is not a consistent feature of PE. While it 
is commonly seen in PE presenting at earlier gestations, in PE 
presenting at term, neonates are not growth restricted and may 
even be large for dates (78).
Thus, the two-stage model has been further refined by Roberts 
and others (77, 79, 80) to take into account the heterogeneous 
nature of PE and the varying contribution from mother and 
infant to the disorder. We now appreciate that normal pregnancy 
is characterized by a low-grade systemic inflammatory response 
and specific metabolic changes, and that virtually all of the fea-
tures of normal pregnancy are simply exaggerated in PE (81–83). 
There is also widespread acceptance that maternal constitutional 
and environmental factors (such as obesity) can interact to 
modulate the risk of PE. Thus, with profoundly reduced placental 
perfusion (or significant “placental loading”), the generation of 
stage 2 may require very little contribution from the mother 
to provide sufficient stress to elicit the maternal syndrome. In 
this setting, almost any woman will develop PE. Conversely, the 
woman with extensive predisposing constitutional sensitivity 
could develop PE with very little reduced perfusion, or minimal 
FigURe 1 | Two main sources (fetal and maternal) can drive a 
pregnancy toward preeclampsia.
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“placental loading.” As with many complex disorders, multiple 
factors can affect disease development positively or negatively, 
with a convenient representation of the two main negative 
sources (fetal and maternal) being that of a see-saw (84), as in 
Figure 1.
While this explains the inconsistencies of the two-stage model, 
the precise mechanisms (1) underlying the initial poor placenta-
tion and (2) linking placental stress and the maternal syndrome 
have still not been fully elucidated.
Much recent research in PE has focused on various angiogenic 
factors, including the pro-angiogenic factors vascular endothe-
lial growth factor (VEGF) and placental growth factor (PlGF) 
and the two anti-angiogenic proteins, such as soluble endoglin 
(sEng) and soluble fms-like tyrosine kinase 1 (sFlt-1). Recent 
data suggest that alterations in circulating angiogenic factors 
play a pathogenic role in PE. These angiogenic factors tightly 
regulate angiogenesis and are also essential for maintenance of 
normal vessel health. Consequently, the synthesis and action of 
these factors and their receptors in the uterine bed and placenta 
are essential for normal placental development and pregnancy 
(85,  86). In PE, increased levels of the anti-angiogenic sFlt-1 
and sEng trap circulating VEGF, PlGF, and transforming growth 
factor-β (TGF-β), respectively. A myriad of data support the idea 
that circulating levels of these factors alone, or in combination, 
can be used to predict PE (87–89) (and see below under PE 
biomarkers), but in line with the heterogeneous nature of PE, 
these data are somewhat inconsistent and their performance as 
biomarkers seems limited to disease with significant placental 
loading (8). Therefore, angiogenic dysregulation would appear 
unlikely to be the sole link between the stressed placenta and 
endothelial dysfunction and the clinical manifestations of the 
disease.
Notwithstanding these many inconsistencies, the central role 
of the placenta as a source of “toxin,” in a condition regarded, 
and indeed often named, as “toxemia of pregnancy” (90–92) 
cannot be refuted. The uncertainty regarding the nature of the 
toxin continues, and other placental sources of endothelial 
dysfunction include syncytiotrophoblast basement membrane 
fragments (STBM) (93) and endothelial progenitor cells (EPC) 
(94); an increase of reactive oxygen species over scavenging by 
antioxidants (95, 96) has also been promoted.
The Bradford Hill criteria for causation of a disease Y by an 
environmental factor X (97) are as follows: (1) strength of associa-
tion between X and Y, (2) consistency of association between X 
and Y, (3) specificity of association between X and Y, (4) experi-
ments verify the relationship between X and Y, (5) modification 
of X alters the occurrence of Y, and (6) biologically plausible cause 
and effect relationship.
In general terms (98), if we see that two things (A and B) 
co-vary in different circumstances, we might infer that A causes 
B, that B causes A, or that something else (C) causes both B 
and A, whether in series or parallel. To disentangle temporal 
relations requires a longitudinal study. The job of the systems 
biologist doing systems medicine is to uncover the chief actors 
and the means by which they interact (99), in this way fulfilling 
the Bradford Hill postulates, a topic to which we shall return at 
the end.
In infection microbiology, and long predating the Bradford 
Hill criteria, the essentially equivalent metrics are known 
[widely, but somewhat inaccurately (100)] as the Koch or 
Henle–Koch postulates (i.e., criteria). They involve assessing 
the correlation of a culturable organism with the presence of 
a disease, the cure of the disease (and its symptoms) upon 
removal of the organism, and the development of the disease 
with (re)inoculation of the organism. They are of great histori-
cal importance but present us with three main difficulties here. 
The first is that we cannot apply the third of them to humans 
for obvious ethical reasons. The second (see also below) and 
related one is that we cannot usefully apply them in animal 
models because none of the existing models recapitulates 
human PE well. Finally, as widely recognized (100–107), 
they cannot be straightforwardly applied when dealing with 
dormant bacteria or bacteria that are otherwise refractory to 
culture.
Our solution to this is twofold: (i) we can assess the first 
two using molecular methods if culturing does not work and 
(ii) we exploit the philosophy of science principle known as 
“coherence” (108–112). This states that if a series of ostensibly 
unrelated findings are brought together into a self-consistent 
narrative and that narrative is thereby strengthened. Our sys-
tems approach purposely represents a “coherence” in the sense 
given.
Overall, known biochemical associations with PE come into 
four main categories, such as abnormal trophoblast invasion, 
oxidative stress, inflammation and altered immune response, and 
anti-angiogenic responses (Figure 2). Each of these can contrib-
ute directly to PE, and although they can interact with each other 
(black arrows), no external or causal source is apparent. Figure 2 
has been redrawn from a very nice review by Pennington and 
colleagues (113), which indicates four main generally accepted 
“causes” (or at least accompaniments) of PE as the four outer 
colored circles. As illustrated with the black two-way arrows, 
many of these also interact with each other. What is missing, in 
FigURe 2 | There are four main “causes” of preeclampsia, represented by the colored outer circles, and these can also interact with each other.  
That part of the figure is redrawn from Pennington et al. (113). In addition, we note here, as the theme of this review, that microbes can themselves cause each of 
the features in the outer colored circles to manifest.
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a sense, is then what causes these causes, and that is the nub of 
our argument here. Since we now know (and describe below) 
that microbes can affect each of these four general mechanisms, 
we have added these routes to Figure  1 (using pink arrows) 
where dormant, resuscitating, or growing microbes are known 
to contribute.
In a similar vein, Magee and colleagues (114) have nicely set 
down their related analysis of the causes and consequences of 
PE, with a central focus (redrawn in Figure 3) on endothelial 
cell activation. While bearing much similarity in terms of 
overall content to the analysis of Pennington and colleagues 
(113), and ours above, it again lacks a microbial or infection 
component as a causative element, but importantly does note 
that infection and/or inflammation can serve to lower the 
threshold for PE in cases of inadequate placentation. In our 
view, microbes can also enter following normal placentation if 
their dormant microbiome begins to wake up and/or to shed 
inflammagens.
Heritability
The question of the extent of heritability of PE (susceptibility) is 
of interest. Although this seems to vary widely in different stud-
ies (Table 1), a number of candidate gene studies (37, 115–118) 
imply that a susceptibility to PE is at least partly heritable, 
consistent with the variance in all the other “risk factors” of 
Table  1 [and  see  Ref. (6)]. As with all the other gene associa-
tion studies where phenotypic (“lifestyle”) information is absent 
(119–121), it is not possible to ascribe the heritability to genetics 
alone, as opposed to an interaction of a genetic susceptibility (e.g., 
in the HLA system) with environmental factors (117), such as 
cytomegalovirus infection (122).
inflammation
Preeclampsia is accompanied by oxidative stress (123, 124) and 
inflammation and, thus, shares a set of observable properties 
with many other (and hence related) inflammatory diseases, 
be they vascular (e.g., atherosclerosis), neurodegenerative (e.g., 
Alzheimer’s, Parkinson’s), or “metabolic” (type 1 and 2 diabetes). 
It is thus at least plausible that they share some common etiolo-
gies, as we argue here, and that knowledge of the etiology of these 
diseases may give us useful clues for PE.
As well as raised levels of inflammatory cytokines that consti-
tute virtually a circular definition of inflammation, we and others 
have noted that all of these diseases are accompanied by dys-
regulation of iron metabolism (84, 125, 126), hypercoagulability 
and hypofibrinolysis (127, 128), blood microparticles (126), and 
changes in the morphology of fibrin fibers [e.g., Ref. (129–134)] 
and of erythrocytes [e.g., Ref. (127, 132–137)].
FigURe 3 | Another detailed representation of factors known to cause or accompany Pe, redrawn from Magee et al. (114).
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In addition, we and others have recognized the extensive evi-
dence for the role of a dormant blood and/or tissue microbiome in 
these (138–143) and related (144–147) diseases, coupled in part 
with the shedding of highly inflammagenic bacterial components 
such as Gram-negative lipopolysaccharide (LPS) and their Gram-
positive cell wall equivalents such as lipoteichoic acids (148). (We 
shall often use the term “LPS” as a “shorthand,” to be illustrative of 
all of these kinds of highly inflammagenic molecules.)
The purpose of this review, outlined as a “mind map” in 
Figure 4, is thus to summarize the detailed and specific lines of 
evidence suggesting a very important role of a dormant microbial 
component in the etiology of PE [and see also Ref. (138)]. To 
do this, we must start by rehearsing what is meant by microbial 
dormancy.
bacterial viability
In microbiology, we usually consider microbes as being in one 
of the three “physiological macrostates” (Figure  5). The defi-
nition of a “viable” bacterium is normally based on its ability 
to replicate, i.e., “viability” =  culturability (149–151). In this 
sense, classical microbiology has barely changed since the time 
of Robert Koch, with the presence of a “viable” microorgan-
ism in a sample being assessed via its ability to form a visible 
colony on an agar plate containing suitable nutrients. However, 
it is well known, especially in environmental microbiology 
[“the  great  plate count anomaly” (152)], that only a small 
percentage of cells observable microscopically is typically cul-
turable on agar plates. In principle, this could be because they 
are/were “irreversibly” non-culturable (operationally “dead”), 
or because our culture media either kill them (153) or such 
media lack nutrients or signaling molecules necessary for their 
regrowth (154, 155) from an otherwise dormant state (156, 
157). These statements are true even for microbes that appear 
in culture collections and (whose growth requirements) would 
be regarded as “known.”
However, it is common enough in clinical microbiology that 
we detect the existence or presence of “novel” microbial patho-
gens with obscure growth requirements before we learn to culture 
them; this is precisely what happened in the case of Legionella 
pneumophila (158–161), Tropheryma whipplei [Whipple’s disease 
(162, 163)], and Coxiella burnetii [the causative agent of Q fever 
(164, 165)]. Even Helicobacter pylori was finally brought into 
culture on agar plates only because an unusually long Easter holi-
day break meant that the plates were incubated for an extended 
period of 5 days (rather than the normal 2) before being thrown 
out (166,  167)! Consequently, there is ample precedent for the 
presence of “invisible” microbes to go unremarked before they 
are discovered as the true cause of a supposedly non-infectious 
disease, even when they are perfectly viable (culturable) accord-
ing to standard analyses.
FigURe 5 | The chief physiological macrostates exhibited by microorganisms.
FigURe 4 | A mind map of the overall structure of the review.
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Dormancy
Dormancy for a microbe is defined operationally as a state, com-
monly of low metabolic activity, in which the organism appears 
not to be viable in that it is unable to form a colony but where it is 
not dead in that it may revert to a state in which it can do so, via 
a process known as resuscitation (156, 157). However, an impor-
tant issue (and see above) is that dormant bacteria do not typically 
fulfill the Koch–Henle postulates (100–103), and in order for 
them to do so it is necessary that they be grown or resuscitated. 
This is precisely what was famously done by Marshall and Warren 
when they showed that the supposedly non-infectious disease of 
gastric ulcers was, in fact, caused by a “novel” organism called 
H. pylori (168, 169). One of the present authors showed in labora-
tory cultures of actinobacteria that these too could enter a state 
of true dormancy (170, 171) [as is well known for Mycobacterium 
tuberculosis, e.g., Ref. (172–176)], and could be resuscitated by 
a secreted growth factor called Rpf (177–181). This RPF family 
has a very highly conserved motif that is extremely immunogenic 
(182, 183), and it is presently under trials as a vaccine against 
M. bovis.
PRevAleNCe OF DORMANT, 
PeRSiSTeNT, OR lATeNT bACTeRiA  
iN iNFeCTiON MiCRObiOlOgY
It is worth stressing here that the presence of dormant or latent 
bacteria in infection microbiology is well established; one-third of 
humans carry dormant M. tuberculosis [e.g., Ref. (175, 184–187)], 
most without reactivation, while probably 50–100% are infected 
with H. pylori, most without getting ulcers or worse (188, 189). 
As with the risk factors in Table 1, the organisms are merely or 
equivalently “risk factors” for these infectious diseases and are 
effectively seen as causative only when the disease is actually 
manifest.
In a similar vein, so-called persisters are phenotypic variants 
of infectious microbes that resist antibiotics and can effectively 
lie in hiding to resuscitate subsequently. This is also very well 
established [e.g., Ref. (139, 190–203)]. In many cases, they can 
hide intracellularly (204), where antibiotics often penetrate 
poorly (205) because the necessary transporters (206–209) are 
absent. This effectively provides for reservoirs of reinfection, e.g., 
for Staphylococcus aureus (210), Bartonella spp. (211), and – most 
pertinently here – for the Escherichia coli involved in urinary tract 
(re)infection (212–215). The same intracellular persistence is true 
for parasites such as Toxoplasma gondii (216).
Thus, the main point of the extensive prevalence of microbial 
dormancy and persistence is that microbes can appear to be 
absent when they are, in fact, present at high concentrations. 
This is true not only in cases where infection is recognized as the 
cause of disease but, as we here argue, such microbes may be an 
important part of diseases presently thought to lack an infectious 
component.
iron and inflammation
It is well known that [with the possible exception of Borrelia 
(217, 218)] a lack of free iron normally limits microbial growth 
in vivo [e.g., Ref. (219–243)], and we have reviewed previously 
(84, 125, 126) the very clear iron dysregulation accompanying PE 
[e.g., Ref. (90, 244–256)].
This has led to the recognition (128, 139, 141) that the source 
of the continuing inflammation might be iron-based resuscita-
tion of dormant microbes that could release well known and 
highly potent inflammagens such as LPS. Indeed, we have shown 
that absolutely tiny (highly substoichiometric) amounts of LPS 
can have a massive effect on the blood clotting process (257), 
potentially inducing β-amyloid formation directly (258, 259) 
[something, interestingly, that can be mimicked in liquid crystals 
(260, 261)]. The overall series of interactions envisaged [see also 
Kell et al. (139)] is shown in Figure 6.
As pointed out by a referee, worldwide, iron deficiency anemia 
is associated with increased perinatal morbidity and mortality, 
predominantly in low resource settings. This is most recently 
and comprehensively reviewed by Rahman and colleagues 
(262). This meta-analysis (262) found that in low- and middle-
income countries, maternal hemoglobin concentrations <10 or 
<11  g  dL−1 or hematocrit values <33 or <34% accounted for 
12% of low birth weight, 19% of preterm births (PTBs), and 18% 
of perinatal mortality. However, the independent contribution 
of iron deficiency is difficult to define, especially since in low 
resource settings anemia is often not found in isolation but as 
part of a wider spectrum of nutritional insufficiencies (especially 
vitamins and folic acid) or as a result of parasitic infection. These 
can increase susceptibility to other insults such a hemorrhage or 
infection, also common in low resources settings. In addition, the 
exact speciation and hence availability of iron may be important 
(not just the total amount). Thus, the hypothesis presented here 
is that iron in excess or under certain physiological conditions can 
be, and indeed is, equally detrimental to maternal health. There is 
a likely a “Goldilocks” concentration of iron which is optimal for 
maternal and neonatal health, and the authors are proposing the 
selected use of treatments such as statins or iron chelators in the 
at-risk population, rather than as a broad panacea. Furthermore, 
the use of statins to prevent pregnancy complications is far from 
controversial (see also below). There are at least two registered 
current trials of statins to prevent PE (ISRCTN17787139 and 
ISRCTN23410175).
Detecting Dormant Microbes
By definition, dormant bacteria escape detection by classical 
methods of assessing viability that involve replication on agar 
plates. Other growth-associated methods include measurements 
involving changes in turbidity (263), including an important but 
now rather uncommon technique referred to as the “most prob-
able number” (MPN). The MPN involves diluting samples serially 
and assessing by turbidity changes in the presence of growth/no 
growth. Look-up tables based on Poisson statistics enable estima-
tion of the number of cells or propagules that were present. A par-
ticular virtue is that they allow dormant and “initially viable” cells 
to be discriminated via “dilution to extinction” (171), thereby 
avoiding many artifacts (157). As mentioned earlier, preincuba-
tion in a weak nutrient broth (171, 264) was instrumental in 
allowing the discovery (177) of an autocrine “wake-up” molecule 
necessary for the growth of many actinobacteria.
FigURe 6 | An 11-stage systems biology model of the factors that we consider cause initially formant microbes to manifest the symptoms (and 
disease) of preeclampsia.
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Other more classical means of detecting microbes, but 
not whether they were culturable, involved microscopy (190, 
265–268) or flow cytometry (269) with or without various stains 
that reflected the presence or otherwise of an intact cell wall/
membrane (170, 270–277). These stains are sometimes referred to 
as “viability” stains, but this is erroneous as they do not measure 
“culturability.” Readers may also come upon the term “viable-
but-not-culturable”; however, since viable = culturable, this is an 
oxymoron that we suggest is best avoided (157). Other methods 
involved measurement of microbial products, e.g., CO2 (278, 
279), or changes in the conductivity or impedance of the growth 
medium (263, 280–282).
Most importantly, however, dormant (as well as culturable) 
cells may be detected by molecular means, nowadays most com-
monly through PCR and/or sequencing of the DNA encoding 
their small subunit ribosomal RNA (colloquially “16S”) (283–297) 
or other suitable genes. It is clear that such methods will have a 
major role to play in detecting, identifying, and quantifying the 
kinds of microbes that we argue lie at the heart of PE etiology.
A Dormant blood Microbiome
Of course, actual bacteremia, the presence of replicable bacteria 
in blood, is highly life-threatening (298), but – as emphasized – 
viability assays do not detect dormant bacteria. When molecular 
detection methods are applied to human blood, it turns out that 
blood does indeed harbor a great many dormant bacteria [e.g., 
Ref. (299–309)]; they may also be detected ultramicroscopically 
[e.g., Ref. (139–141, 190, 267, 300, 310)] or by flow cytometry 
(311), and dormant blood and tissue microbes probably underpin 
a great many chronic, inflammatory diseases normally consid-
ered to lack a microbial component (139–141, 144–147, 190, 
267, 268, 302, 312–321). Multiple arguments serve to exclude 
“contaminants” as the source of the bacterial DNA (141): (1) 
there are significant differences between the blood microbiomes 
of individuals harboring disease states and nominally healthy 
controls, despite the fact that samples are treated identically; (2) 
the morphological type of organism (e.g., coccus vs. bacillus) 
seems to be characteristic of particular diseases; (3) in many cases, 
relevant organisms lurk intracellularly, which is hard to explain 
by contamination; (4) there are just too many diseases where 
bacteria have been found to play a role in the pathogenesis, that all 
of them may be caused by contamination; (5) the actual numbers 
of cells involved seem far too great to be explicable by contami-
nation; given that blood contains ~5 × 109 erythrocytes mL−1, if 
there was just one bacterial cell per 50,000 erythrocytes this will 
equate to 105 bacteria mL−1. These are big numbers, and if the cells 
were culturable, that number of cells would be the same as that 
ordinarily defining bacteriuria.
A recent study by Damgaard and colleagues (306) is of 
particular interest here. Recognizing the strong mismatch 
between the likelihood of an infection post-transfusion [very 
high (306)] and the likelihood of detecting culturable microbes 
in blood bank units (negligible, ca. 0.1%) (306, 322), Damgaard 
et  al. reasoned that our methods of detecting and culturing 
these microbes might be the problem. Certainly, taking cells 
from a cooled blood bag and placing them onto an agar plate 
at room temperature that is directly exposed to atmospheric 
levels of gaseous O2 is a huge stress leading to the production of 
TAble 2 | Many studies have identified a much greater prevalence of infectious agents in the blood or urine of these exhibiting Pe than in matched 
controls.
Microbes Comments Reference
Chlamydia pneumoniae IgG seroprevalence and gDNA associated with PE (p < 0.0001) (349)
IgG (but not IgA or IgM) associated with PE, OR = 3.1 (350)
Significantly greater numbers with PE, and reversion under antichlamydial treatment (351)
Chlamydia trachomatis Increased risk of PE, OR = 7.2 or 1.6 based on serology (352, 353)
Cytomegalovirus RR for PE 1.5 if infected with CMV (354) [see also Xie et al. (355)]
Helicobacter pylori Seropositivity or DNA. OR = 2.7 or 26 if CagA seropositivity (343) and editorial (356)
IgG seropositivity 54% PE vs. 21% controls (357)
Anti-CagA antibodies cross-react with trophoblasts and could inhibit placentation (358)
2.8× greater seropositivity in PE group (359)
OR = 2.86 for seropositivity in PE, correlated with high malondialdehyde levels (360)
Wide-ranging review of many studies showing PE more prevalent after Hp infection (361)
Seropositivity PE:control = 84:32% (p < 0.001) (362)
OR for seropositivity 1.83 (p < 0.001) (363)
Seropositivity PE:control 86:43% (p < 0.001) (364)
Human papillomavirus High-risk human papillomavirus (HR-HPV) presence implies an OR of 2.18 for PE (365)
Meta-analyses Incidence of PE 19% with asymptomatic bacteriuria vs. 3% (primigravid) or 6% (multigravid) 
controls (p < 0.005)
(366)
UTI more than twice as likely in severe preeclamptics than in controls (367)
OR of 1.6 for PE if UTI present (368)
Increased risk of PE OR 1.57 for UTI, 1.76 for periodontal disease (53)
Early application of antibiotics in infection reduced PE by 52% (330)
Any overt infection led to an RR of 2 for PE (54)
UTI has OR of 3.2 for PE; OR = 4.3 if in third trimester (369)
UTI has OR of 1.3 for mild/moderate and 1.8 for severe PE (370)
Increased risk of PE with UTI (OR 1.22) or antibiotic prescription (OR 1.28) (371)
OR of 6.8 for symptomatic bacteriuria in PE vs. controls (372)
OR 1.3–1.8 of mild or severe PE if exposed to UTI (373)
OR 1.4 for PE following UTI (374)
OR 1.3 for PE after UTI (375)
Meta-analyses showing associations between PD and PE (376–378)
Plasmodium falciparum (malaria) Indications that infection with malaria is associated with PE (379)
1.5 RR for PE if malarial (380)
Seasonality: 5.4-fold increase in eclampsia during malaria season (381)
Preeclampsia was significantly associated with malaria infection during pregnancy (p < 0.03) and 
69.7% of cases of preeclampsia with infected placenta might be attributable to malaria infection
(382)
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“reactive oxygen species” (125, 323), that might plausibly kill any 
dormant, injured, or even viable microbes. Thus, they incubated 
samples from blood on a rich medium (trypticase soy agar) for 
a full week, both aerobically and anaerobically. Subsequent PCR 
and sequencing allowed them to identify specific microbes in 
some 35–53% of the samples. Thus, very careful methods need 
to be deployed to help resuscitate bacteria from physiological 
states that normally resist culture, even when these bacteria are 
well-established species. This is very much beginning to happen 
in environmental microbiology [e.g., Ref. (154, 324–326)], and 
such organisms are rightly seen as important sources of novel 
bioactives (327, 328).
As reviewed previously (139–143), the chief sources of these 
blood microbes are the gut microbiome, the oral microbiome 
[periodontitis (329)], and via UTIs. Consequently, if we are 
to argue that there is indeed a microbial component to PE, we 
should expect to see some literature evidence for it (53, 54, 
138, 330–332). In what follows we shall rehearse the fact that it 
is voluminous.
DiReCT eviDeNCe FOR A ROle OF 
iNFeCTiOUS AgeNTS iN Pe
Although we recognize that many of the more molecular meth-
ods cannot distinguish culturable from dormant microbes, quite 
a number of studies have explicitly identified infection as a cause 
of PE (Table 2). The commonest microbe seems to be H. pylori; 
while it is most famously associated with gastric ulcers (168, 169, 
333), there are many other extragastric manifestations [e.g., Ref. 
(334–342)]. The odds ratio of no less than 26 in PE vs. controls 
when the strains can produce CagA antigens is especially striking, 
not least because it provides a mechanistic link to poor tropho-
blast invasion via a mechanism involving host antibodies to CagA 
cross-reacting with trophoblasts (343, 344), and circulating (345) 
in microparticles (346) or endosomes (347, 348).
In contrast to the situation in PE, albeit severe PE is associated 
with iatrogenic PTBs, there is a widespread recognition [e.g., Ref. 
(383–410)] that infection is a common precursor to PTB in the 
absence of PE. The failure of antibiotics to help can be ascribed 
TAble 3 | evidence for microbes in placental tissues, including those with Pe.
Organisms Comments Reference
Multiple, including Actinobacillus 
actinomycetemcomitans, Fusobacterium nucleatum
Many more in PE placentas relative to controls (p ≤ 0.0055) (451)
Multiple Half of second-trimester pregnancies have culturable or PCR-detectable bacteria/mycoplasmas (419)
Multiple 38% of placental samples were positive for selected bacteria and viruses (452)
Bifidobacterium spp. and Lactobacillus rhamnosus Bifidobacteria and L. rhamnosus (from gut) detected in 31/34 and 33/34 placental samples (420)
Multiple Detectable in 27% of all placentas and 54% of spontaneous preterm delivery (421)
Multiple 16S/NGS, major review (400)
Multiple From 16S and NGS analysis of placental tissue of 7 PE patients (12.5%) (controls all negative) (453)
E. coli and L. monocytogenes When added ex vivo can migrate to extravillous trophoblasts (422)
Multiple Review, with some focus on preterm birth (423)
Multiple Overview, some focus on preterm birth (425)
Multiple Good recent overview, with possible implication of a physiological role (426)
Multiple 320 placentas; changed microbiome as a function of excess gestational weight gain (427)
Multiple One-third of placentas from preterm births were culture-positive (428)
Multiple Major differences in placental microbiome in preterm birth (432)
Plasmodium falciparum (malaria) Increased likelihood of PE (380)
Plasmodium falciparum (malaria) Reviews of placental malaria (454, 455)
Porphyromonas gingivalis OR of PE = 6.3 if detected in umbilical cord (456)
Porphyromonas gingivalis OR 7.59 in placental tissues with hypertensive disorders (457)
Treponema denticola OR 9.39 in placental tissues with hypertensive disorders (457)
Meta-analysis Widespread occurrence of microbes in female genital tract during pregnancy (403)
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to their difficulty of penetrating to the trophoblasts and placental 
regions. Unfortunately, no proteomic biomarkers have yet been 
observed as predictive of PTB (411, 412). In a similar vein, and if 
we are talking about a time of parturition that is very much more 
“preterm,” we are in the realm of miscarriages and spontaneous 
abortions and stillbirths, where infection again remains a major 
cause (413–416). Here, we note that early or pre-emptive antibiotic 
therapy has also proved of considerable value in improving out-
comes after multiple spontaneous abortions (417).
vaginal, Placental, and Amniotic Fluid 
Microbiomes in Pe
It might be natural to assume that the placenta is a sterile organ, 
like blood is supposed to be. However, various studies [modulo 
the usual issues of contamination (418)] have shown the presence 
of microbes in tissues including the placenta (400, 409, 419–432), 
vagina (393, 433–440), uterus (391, 441, 442), amniotic fluid (430, 
443–448), and follicular fluid (449, 450), and how these may vary 
significantly in PE [we do not discuss other pregnancy disorders 
such as small for gestational age (SGA) and intrauterine growth 
restriction (IUGR)]. We list some of these in Table 3.
ORigiNS OF A blOOD AND TiSSUe 
MiCRObiOMe
As assessed previously (139–141) over a large literature, the chief 
source of blood microbes is the gut (426), with another major entry 
point being via the oral microbiome (especially in periodontitis, 
see below). For rheumatoid arthritis (142, 458–460) and diseases 
of pregnancy, UTI (see below and Table TT) also provides a major 
source.
gut Origins of blood Microbes and lPS
We have recently rehearsed these issues elsewhere (139–141), 
so a brief summary will suffice. Clearly, the gut holds trillions 
of microbes, with many attendant varieties of LPS (461), so 
even low levels of translocation [e.g., Ref. (462–464)], typically 
via Peyer’s patches and M cells, provide a major source of the 
blood microbiome. This may be exacerbated by intra-abdominal 
hypertension and overeating (465–467) that can indeed stimulate 
the translocation of LPS (468). For reasons of space and scope, we 
do not discuss the origins and translocation of microbes in breast 
milk (469) nor the important question of the establishment of a 
well-functioning microbiome in the fetus and neonate (470), and 
the physiological role of the mother therein.
Preeclampsia and Periodontal Disease
One potential origin of microbes that might be involved in, or 
represent a major cause of, PE is the oral cavity, and in particular 
when there is oral disease (such as periodontitis and gum bleed-
ing) that can allow microbes to enter the bloodstream. If this is 
a regular occurrence one would predict that PE would be much 
more prevalent in patients with pre-existing periodontitis [but cf. 
Ref. (471) for those in pregnancy] than in matched controls; this 
is indeed the case (Table 4). As with many of the tables herein, the 
odds ratios are far beyond anything that might weakly be referred 
to as an “association.”
Urinary Tract infections
A particular feature of UTIs is the frequency of reinfection 
(497–504). This is because the organisms can effectively “hide” 
in bladder epithelial cells as the so-called “quiescent intracellular 
reservoirs” (212, 501, 503, 505–509) of (presumably) dormant 










Massive (OR = 0.092) protection against PE in 




52% decrease in PE following 10-day antibiotic 
therapy
(330)
TAble 4 | Periodontal disease (PD) and preeclampsia.
Organisms Comments Reference
Meta-analyses OR of PE increased 3.69-fold if PD before 32 weeks (472)
OR of 3 for the development of PE if ureaplasmas present at first antenatal visit (473)
OR 5.56 for PD preceding PE (474)
OR 2.1 for preceding PE (475)
Extensive overview of role of oral health and periodontal disease in PE (476)
OR 3.71 for PE if history of periodontal treatment (477)
Excellent overview of likely relationship between PD and PE (478)
OR = 8.6 or 2.03 for PE if PD was present vs. controls (479)
Strong association between PD and PE (p < 0.01) (480)
Overview with many references (481)
OR for association between PD and PE = 3.73. No correlation with TNF-α or IL (482)
OR 2.46 PE:controls (483)
Excellent overviews, focusing on means of transport of microbes from mouth to reproductive tissue (484) [see also Bobetsis et al. (485)]
Relationship between C-reactive protein, PE, and severity of PD (486)
Adjusted PE RR 5.8 for Women with periodontal disease and CRP >75th percentile compared to 
women without periodontal disease
(487)
PD prevalence 65.5% and significantly higher (p < 0.0001) in females with hypertension (RR = 1.5) (488)
Meta-analysis (489)
Periodontal bacteria “much more prevalent” in PE than controls, but OR not given (490)
Overview, stressing role of LPS (491)
Overview and meta-analysis of 25 studies (492)
OR 4.79–6.6 for PE is PD (493)
Porphyromonas gingivalis Its LPS inhibits trophoblast invasion (494)
OR = 3 overall (495)
Not stated Significantly higher periodontal probing depth and clinical attachment level scores in the preeclamptic 
group compared with controls (2.98 vs. 2.11 and 3.33 vs. 2.30, respectively).
(496)
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cells that can resuscitate. This is why reinfection is often from the 
same strains that caused the original infection (510–514). Other 
complications can include renal scarring (515). Bacteriuria (often 
asymptomatic) is a frequent occurrence in pregnancy [e.g., Ref. 
(373, 375, 473, 516–522)], and the frequency of UTI as a source 
of microbes causing PE is clear from Table 2.
From blood to and from the Placenta:  
A Role for Microparticles
We and others have noted the fact that many chronic, inflamma-
tory disease are accompanied by the shedding of various antigens 
and other factors; typically they pass through the bloodstream 
as microparticles (126, 140, 523–530), sometimes known as 
endosomes (345, 347, 348, 524, 531) [and see later under micro-
RNAs (miRNAs)]. Similarly, LPS is normally bound to proteins 
such as the LPS-binding protein and apoE (140). Given their 
prevalence, their role in simply finding their way from maternal 
blood to placenta, and the fact that we discussed them extensively 
in two previous reviews (126, 140), we do not discuss them fur-
ther here.
eviDeNCe FROM ANTibiOTiC THeRAPieS
Antibiotic drug prescriptions (532–534) may be seen as a proxy 
for maternal infection, so if dormant (and resuscitating and 
growing) bacteria are a major part of PE etiology one might 
imagine an association between antibiotic prescriptions and PE. 
According to an opposite argument, antibiotics and antibiotic 
prescriptions given for nominally unrelated infections (UTI, 
chest, etc., and in particular diseases requiring long-term anti-
infective medication that might even last throughout a preg-
nancy) might have the beneficial side-effect of controlling the 
proliferation of dormant cells as they seek to resuscitate. There 
is indeed some good evidence for both of these, implying that it 
is necessary to look quite closely at the nature, timing, and dura-
tion of the infections and of the anti-infective therapy relative 
to pregnancy. A summary is given in Table 5. A confounding 
factor can be that some (e.g., the antiretroviral) therapies are 
themselves quite toxic (535, 536); while the OR for avoiding PE 
was 15.3 in one study of untreated HIV-infected individuals vs. 
controls, implying (as is known) a strong involvement of the 
immune system in PE, the “advantage” virtually disappeared 
upon triple-antiretroviral therapy (537). Overall, it is hard to 
draw conclusions from antiretrovirals (538, 539). However, we 
have included one HIV study in the table. Despite a detailed 
TAble 6 | Molecular examples of bacterial antigens that can elicit 
antibodies that stop successful trophoblast implantation or stimulate 
parturition.
Organism Antigen and comments Reference
Gram-negatives LPS can stimulate parturition, via 
corticotropin-releasing hormone
(572)
Gram-negatives LPS can stimulate parturition, via MAPKinase (559)
Helicobacter pylori Anti-CagA antibodies cross-react with 




LPS inhibits trophoblast invasion (494)
Various Antiphospholipid antibodies (that can be 
induced by microbes, see above)
(573–576)
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survey, we found no reliable studies with diseases such as Lyme 
disease or tuberculosis, where treatment regimens are lengthy, 
that allowed a fair conclusion as to whether antibiotic treatment 
was protective against PE. However, we do highlight the abso-
lutely stand-out study of Todros and colleagues (540), who noted 
that extended spiramycin treatment (of patients with T. gondii) 
gave a greater than 10-fold protection against PE, when the 
parasite alone had no effect (541). This makes such an endeavor 
(assessing the utility of early or pre-emptive antibiotics in PE) 
potentially highly worthwhile.
ROle OF lPS iN Pe
It is exceptionally well known that LPS (sensu lato) is highly 
inflammagenic, and since one of us recently reviewed that litera-
ture in extenso (140) this is not directly rehearsed here. However, 
since we are arguing that it has a major role in PE naturally or 
in vivo, we do need to ask whether the literature is consistent with 
this more focused question. The answer is, of course, a resound-
ing “yes.” Notwithstanding that only primates, and really only 
humans, are afflicted by “genuine” PE, so the genuine utility of 
rodent models is questionable (543), even if some can recapitulate 
elements of the disease (544, 545). Hence, it is somewhat ironic 
that there are a number of animal models in which LPS (also 
known as “endotoxin”) is used experimentally to induce a condi-
tion resembling PE [e.g., Ref. (546–551) and also see Ref. (552)]. 
We merely argue that it is not a coincidence that exogenous 
administration of LPS has these effects, because we consider that 
it is, in fact, normally one of the main mediators of PE. Also note, 
in the context of gestational diabetes, that serum levels of LPS are 
raised significantly in both type 1 (466, 553) and type 2 (554–556) 
diabetes.
The standard sequelae of LPS activation, e.g., TLR signaling 
and cytokine production, also occur in PE (557–559), bolstering 
the argument that this is precisely what is going on. In a similar 
vein, double-stranded RNA-mediated activation of TLR3 and 
TLR7/8 can play a key role in the development of PE (560–562). 
What is new here is our recognition that LPS and other inflam-
magens [e.g., Ref. (563–565)] may continue to be produced and 
shed by dormant and resuscitating bacteria that are generally 
invisible to classical microbiology.
eFFeCTS OF lPS AND OTHeR 
MiCRObiAl ANTigeNS ON DiSRUPTiNg 
TROPHOblAST iNvASiON AND/OR 
STiMUlATiNg PARTURiTiON
As with other cases of cross-reactivity such as that of various anti-
gens in Proteus spp. that can cause disease in rheumatoid arthritis 
(458–460), the assumption is that various microbial antigens can 
lead to the production of (auto-)antibodies that attack the host, 
in the present case of interest by stopping the placentation by 
trophoblasts. This is commonly referred to as “molecular mim-
icry” [e.g., Ref. (566–569)] and may extend between molecular 
classes, e.g., peptide/carbohydrate (570, 571). Table 6 shows some 
molecular examples where this has been demonstrated.
In many cases, the actual (and possibly microbial) antigens are 
unknown, and clearly the microbial elicitation of antibodies to 
anything that might contribute to PE points to multiple potential 
origins. To this end, we note that PE has also been associated with 
antibodies to angiotensin receptors (577–590), to smooth muscle 
(591, 592) [such blocking may be anti-inflammatory (593–595)], 
to adrenoceptors (596), to the M2 muscarinic receptor (597), and 
to Th17 (598) [and see Ref. (599)]. It is not unreasonable that 
epitope scanning of the antibody targets coupled with compara-
tive sequence analysis of potential microbes might light up those 
responsible. In the case of angiotensin II type 1 receptor antibod-
ies, the epitope is considered (600) to be AFHYESQ, an epitope 
that also appears on parvovirus B19 capsid proteins; in the event, 
parvoviruses seem not to be the culprits here (601). However, the 
role of these antibodies in activating the angiotensin receptor is 
also considered to underpin the lowering of the renin–angioten-
sin system that is commonly seen in PE (602–605), but which is 
typically raised during normal pregnancy.
Th-17 is of especial interest here, since these are the helper T 
(Th)-cell subset that produces IL-17. IL-17 is probably best known 
for its role in inflammation and autoimmunity (599, 606–610). 
However, it also has an important role in induction of the protec-
tive immune response against extracellular bacteria or fungal 
pathogens at mucosal surfaces (608, 611–623). Th17 cells seem 
to participate in successful pregnancy processes and can be lower 
in PE (624–626), although more studies show them as higher 
(599, 627–635) or unchanged (636, 637). One interpretation, 
consistent with the present thesis, is that the antimicrobial effects 
of placental IL-17 relative to Treg cells are compromised during PE 
(599, 633, 638).
A NOTe ON THe TeRMiNOlOgY  
OF SePSiS
As one may suppose from the name, sepsis (and the use of words 
like “antiseptic”) was originally taken to indicate the presence 
of culturable organisms in (or in a sample taken from) a host, 
e.g., as in bacteremia. Recognizing that it is the products of bac-
teria, especially cell wall components, that cause the cytokine 
storms that eventually lead to death from all kinds of infection 
(639–643), “sepsis” nowadays has more come to indicate the lat-
ter, as a stage (in the case of established infection) on a road that 
FigURe 7 | Preeclampsia bears some similarities to and may be 
considered as a milder form of, the changes that occur during 
genuine sepsis leading to a systematic inflammatory response 
syndrome, septic shock, and multiple organ dysfunction.
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leads to septic shock and (eventually) to death [with a shockingly 
high mortality, and many failures of initially promising treat-
ments, e.g., Ref. (644, 645), and despite the clear utility of iron 
chelation (84, 125, 646–648)]. In most cases, significant numbers 
of culturable microbes are either unmeasured or absent, and 
like most authors, we shall use “sepsis” to imply the results of 
an infection whether the organisms are detected or otherwise. 
Overall, it is possible to see the stages of PE as a milder form of 
the sepsis cascade on the left-hand side of Figure  7. Figure  7 
compares the classical route of sepsis-induced death with the 
milder versions that we see in PE; they are at least consistent with 
the idea that PE is strongly related to the more classical sepsis in 
degree rather than in kind.
PReeClAMPSiA AND NeONATAl SePSiS
If PE is really based on infectious agents, it is reasonable that one 
might expect to see a greater incidence of neonatal sepsis (i.e., 
infection) following PE. While there are clearly other possible 
explanations (e.g., simply a weakened immune system, sometimes 
expressed as neutropenia, after PE), there is certainly evidence 
that this is consistent with this suggestion (649–653).
Pe biOMARKeRS AND iNFeCTiON
Because of the lengthy development of PE during pregnancy, 
there has long been a search for biomarkers (somewhat equivalent 
to the “risk factors” discussed earlier) that might have predictive 
power, and some of these, at both metabolome (15, 654–661) 
and proteome (662–667) level, are starting to come forward. The 
typical experimental design is a case–control, in which markers 
that are raised or lowered significantly relative to the age-matched 
controls are considered to be candidate markers of PE. However, 
just as noted with leukocyte markers (81) and polycystic ovary 
syndrome (PCOS) (668) that does not mean that they might not 
also be markers for other things too, such as infection (669)!
Thus, one prediction is that if dormant and resuscitating bac-
teria are responsible for PE then at least some of these biomarkers 
should also be (known to be) associated with infection. However, 
one obvious point is that the markers may appear only after 
infection, and this may itself be after the first-trimester; clearly 
then these would not then be seen as “first-trimester” biomarkers! 
There are many well-known inflammatory biomarkers that are 
part of the innate [and possibly trained (670)] immune response, 
such as the inflammatory cytokines CRP [cf. Ref. (671, 672)], 
IL-6 (673), IL-1β (674), TNF-α (675), and macrophage migration 
inhibitory factor (MIF) (676), which are also all biomarkers of 
infection (677–681). Certainly, the fact that these increase in PE is 
consistent with a role for an infectious component. However, we 
shall mainly look at other biomarkers that are known to increase 
with PE, and see if they are also known to be biomarkers for (or 
at least changed in the presence of) infection (and see Th17/IL-17 
above), and we next examine this. We shall see that pretty well 
every biomarker that is changed significantly in PE is also known 
to be changed following infection, a series of findings that we 
consider adds very strong weight to our arguments.
PROTeOMiC AND SiMilAR biOMARKeRS 
– CiRCUlATiNg AND PlACeNTAl
What is really needed is a full systems biology strategy [see, e.g., 
Ref. (99, 682–684)] that brings together the actors that interact 
then parametrizes the nature of these interactions in a suit-
able encoding [e.g., SBML (685)] that permits their modeling, 
at least as an ODE model using software such as CellDesigner 
(686), COPASI (687), or Cytoscape (688). Thus, to take a small 
example, “agonistic autoantibodies against the angiotensin II 
type 1 receptor autoantibodies (AT1-AA) are described. They 
induce NADPH oxidase and the MAPK/ERK pathway leading 
to NF-κB and tissue factor activation. AT1-AA are detectable in 
animal models of PE and are responsible for elevation of soluble 
fms-related tyrosine kinase-1 (sFlt1) and soluble endoglin (sEng), 
oxidative stress, and endothelin-1, all of which are enhanced in 
pre-eclamptic women. AT1-AA can be detected in pregnancies 
with abnormal uterine perfusion” (589). Many such players have 
been invoked, and we next list some.
Activin A
Activin A is a member of the TGF-β superfamily. Its levels are 
raised significantly in PE (118, 689–691). However, activin A is 
also well established as a biomarker of infection (692–695).
Calretinin
In a proteomic study of preclamptic vs. normal placentas (696), 
calretinin was one of the most differentially upregulated proteins 
(p = 1.6 × 10−13 for preterm PE vs. controls, p = 8.9 × 10−7 for 
term PE vs. controls), and in a manner that correlated with the 
severity of disease. While calretinin [normally more expressed 
in neural tissue and mesotheliomas (697)] is not normally seen 
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as a marker of infection, it is, in fact, raised significantly when 
Chlamydia pneumoniae infects human mesothelial cells (698).
Chemerin
Chemerin is a relatively recently discovered adipokine, whose 
level can increase dramatically in the first-trimester of preeclamp-
tic pregnancies (699), and beyond (700). Its levels are related to 
the severity of the PE (701–703). Specifically, an ROC curve (704) 
analysis showed that a serum chemerin level >183.5  ng  mL−1 
predicted PE with 87.8% sensitivity and 75.7% specificity (AUC, 
0.845; 95% CI, 0.811–0.875) (699). Papers showing that chemerin 
is also increased by infection (hence inflammation) include (705, 
706); it even has antibacterial properties (707, 708) and was 
protective in a skin model of infection (709, 710). In a study of 
patients with sepsis (711), circulating chemerin was increased 
1.69-fold compared with controls (p = 0.012) and was also pro-
tective as judged by survival. These seem like particularly potent 
argument for a role of chemerin as a marker of infection rather 
than of PE per  se, and for the consequent fact that PE follows 
infection and not vice versa.
Copeptin
Copeptin, a glycosylated polypeptide consisting of the 39 
C-terminal amino acids of arginine vasopressin, has been sug-
gested as “a new biomarker that is specific for preeclampsia” (712), 
and certainly changes during its development (713). However, 
it turns out that it is also essentially a measure of all kinds of 
stresses and adverse events (714–719), including those caused by 
infection (720–729).
Cystatin C
Not least because kidney function is impaired in PE, low molecular 
weight (MW) proteins may serve as biomarkers for it. To this end, 
cystatin C (13 kDa) has been found to be raised significantly in 
PE (730–736); it also contributed to the marker set in the SCOPE 
study (8, 17). Notably, although it certainly can be raised during 
infection (737), it seems to be more of a marker of inflammation 
or kidney function (738, 739).
d-Dimer
“d-dimer” is a term used to describe quite varying forms of fibrin 
degradation products (740). Given that PE is accompanied by 
coagulopathies, it is probably not surprising that d-dimer levels 
are raised in PE (741–745), although this is true for many condi-
tions (746), and some of the assays would bear improvement 
(747, 748). Needless to say, however, raised d-dimer levels are 
also a strong marker for infection (749, 750).
endocan
Endothelial cell-specific molecule-1 (ESM-1), known as endocan, 
is a cysteine-rich dermatan sulfate proteoglycan expressed (and 
sometimes released) by endothelial cells. It has been suggested to 
be a new biomarker for endothelial dysfunction and PE (751, 752). 
It would appear, however, to be a rather less specific inflammatory 
biomarker (753, 754) and is associated with a variety of diseases, 
including chronic kidney disease (755, 756) and cardiovascular 
disease (755). Most pertinently from our perspective, it is also 
raised strongly during sepsis (757–760).
endoglin
Endoglin is the product of a gene implicated (761, 762) in the 
rare disease Hereditary Hemorrhagic Telangiectasia. The role of 
endoglin remains somewhat enigmatic (763). However, endoglin 
levels were 2.5-fold higher in preeclamptic placentas compared to 
normal pregnancies (15.4 ± 2.6 vs. 5.7 ± 1.0, p < 0.01). After the 
onset of clinical disease, the mean serum level of sEng in women 
with preterm PE was 46.4 ng mL−1, as compared with 9.8 ng mL−1 
in controls (p < 0.001) (88). Women with a particular endoglin 
polymorphism (AA) were 2.29 times more likely to develop PE 
than those with the GG genotype (p = 0.008) (764), and endoglin 
is seen as a reasonably good marker for PE (88, 691, 765–768) [cf. 
Ref. (769)]. Again, endoglin levels are raised following infection 
by a variety of organisms (770–773), with a particularly clear 
example that it is a marker of infection coming from the fact that 
there is raised endoglin only in infected vs. aseptic loosening in 
joints following arthroplasty (774). In general, it seems likely 
that these circulating (anti)angiogenic factors are more or less 
markers of endothelial cell damage, just as we have described for 
serum ferritin (126).
Ferritin
The natural iron transporter in blood is transferrin [e.g., Ref. 
(775–780)], present at ca. 1–2  g  L−1, with ferritin being an 
intracellular iron storage molecule, so one is led to wonder why 
there is even any serum ferritin at all (126, 781). The answer is 
almost certainly that it is a leakage molecule from damaged cells 
(126), and when in serum it is found to have lost its iron content 
(782–785). Serum ferritin is, as expected, raised during PE (244, 
246, 249, 253, 255, 786, 787) and in many other inflammatory dis-
eases (126), including infection [e.g., Ref. (788, 789) and above].
microRNAs
microRNAs are a relatively novel and highly important class of 
~22  nt non-coding, regulatory molecules (790–793). Some are 
placenta specific, and those in the circulation [often in endo/
exosomes (794–796)] can be identified during pregnancy 
(797–800), potentially providing a minimally invasive readout 
of placental condition (801–803). There is aberrant expression 
of placenta-specific miRNAs in PE including miR-517a/b and 
miR-517c (804–810) and miR-1233 (811). C19MC is one of the 
largest miRNA gene clusters in humans, maps to chromosome 
19q13.41, and spans a ~100 kb long region. C19MC miRNAs are 
processed from the cluster (812), are primate-specific, conserved 
in humans, and comprise 46 miRNA genes, including the miR-
517 family (813). miR-517 is known to be antiviral (814, 815), 
while miR-517a overexpression is apoptotic (816) and can inhibit 
trophoblast invasion (817). Importantly for our argument, miR-
517 molecules are overexpressed following infection (818, 819).
Neuropeptide Y
Although, as its name suggests, neuropeptide Y is a neurotrans-
mitter, it is also correlated with stress. Certainly, it is related 
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to noradrenaline (see below) that may itself be responsible for 
the raised blood pressure (BP) in PE (820). It is also raised in 
sepsis, where it is considered to counterbalance the vasodilation 
characteristic of septic shock [e.g., Ref. (821, 822)]. The apparent 
paradox of a raised BP in PE and a lowered one in septic shock 
is considered to be related to the very different concentrations of 
endotoxin involved (Figure 7).
NgAl (lipocalin 2, Siderocalin)
Neutrophil gelatinase-associated lipocalin (NGAL) is a lipoca-
lin that is capable of binding catecholate-based siderophores 
(125, 823, 824). As such it is antimicrobial and is also an inflam-
matory or sepsis biomarker (825, 826). Given our interest in iron, 
it is not surprising that it is changed during PE. While one study 
suggested it to be decreased in PE (827), a great many other stud-
ies showed it to be increased significantly in PE, and typically 
in a manner that correlated with PE severity (735,  828–837). 
Pertinently to PE, it is also well established as an early biomarker 
of acute kidney injury (AKI) (838–841). However, it is not a 
specific biomarker for AKI vs. sepsis (839, 842–850) and its 
origin in sepsis differs (851, 852). Of course, it can be the sepsis 
that leads to the AKI (853, 854). Fairly obviously, while it does 
tend to be increased during PE, we again see its direct role as an 
antimicrobial and marker of sepsis as highly supportive of our 
present thesis.
Placental growth Factor
This is a member of the VEGF Family that despite its name has a 
great many activities (855). It is often considered in parallel with 
endoglin and sFlt, with a high sFlt:PlGF ratio being considered as 
especially discriminatory for PE (89, 856–869), i.e., a lower PlGF 
can be diagnostic of PE (769, 870–873). PlGF tends to be raised in 
sepsis unrelated to pregnancy (874, 875), while its lowering in PE 
may be due to the excess sFLT that decreases it (855, 876, 877). In 
one study of a patient with CMV infection and PE, it was, in fact, 
raised (878), while, in the case of IUGR, it was massively lowered 
(879). PlGF alone is thus probably not a useful general marker for 
either PE or sepsis if one is trying to disentangle them, although it 
has clear promise when PE is superimposed on CKD (872, 880).
Procalcitonin
Procalcitonin is the 116 amino acid polypeptide precursor of cal-
citonin, a calcium regulatory hormone. It is another marker that 
has been observed to be raised (according to severity) in preec-
lamptics (742, 881, 882) [but cf. Ref. (713)]. However, it is also a 
known marker of bacterial infections or sepsis (881, 883–891).
Serum Amyloid A
This is an inflammatory biomarker, which was shown to increase 
fourfold in PE in one study (892), was significantly raised in 
another (882), but not in a third (893). However, it is a well-
established (and potent) biomarker for infection/sepsis [e.g., Ref. 
(894–907)]. Defective amyloid processing may be a hallmark of 
PE more generally (908), and of course amyloid can be induced 
by various microbes (317, 319, 909, 910) and their products (257).
Soluble fms-like Tyrosine Kinase 1
The sFlt receptor is a splice variant of the VEGF receptor (766). 
It is raised considerably in PE (691, 767, 856, 862, 864, 911–914) 
and may be causal (545, 590, 915–918). Needless to say, by now, 
we can see that it is also a very clear marker of infection (767, 
919, 920), whose levels even correlate with the severity of sepsis 
(921–923). Of particular note is the fact that sFLT is actually anti-
inflammatory (922).
Thrombomodulin
Soluble thrombomodulin was recognized early as an endothelial 
damage biomarker and is raised in PE (924–934). Interestingly, 
it has been found to have significant efficacy in the treatment of 
sepsis [-based disseminated intravascular coagulation (DIC)] 
(935–943).
TlR4
TLR4 upregulation in preeclamptic placentas (944) is entirely 
consistent with infection and the “danger model” as applied to PE 
(945). As well as LPS activation [reviewed in Kell and Pretorius 
(140)], the heat shock protein 60 of Chlamydia also activates 
TLR4 (138).
visfatin
Visfatin is another adipokine that is raised in PE, approximately 
2-fold in the study of Fasshauer and colleagues (946), and 1.5-fold 
in that of Adali and colleagues (947). However, it was little differ-
ent in a third study (948), while in a different study, it was rather 
lower in PE than in controls (949). This kind of phenomenon 
rather lights up the need for excellent quality studies, including 
ELISA reagents, when making assessments of this type.
Fairly obviously, the conclusion that this long list of biomark-
ers that are raised in PE might be specific “PE” biomarkers is 
challenged very strongly by the finding that they are, in fact, all 
known markers of infection, a finding that in our view strongly 
bolsters the case for an infectious component in PE.
In a similar vein, there are a number of other sepsis markers 
(where sepsis is varied via, or occurs as, an independent vari-
able) that we would predict are likely to be visible as raised in PE 
patient. These might include (680, 950) PAI-1, sE-selectin (951), 
and sVCAM-1 (921). In particular, Presepsin looks like a poten-
tially useful marker for sepsis (888, 889, 952–961), but we can find 
no literature on its use as a PE biomarker, where we predict that 
it may also be raised.
MeTAbOlOMiC biOMARKeRS
For fundamental reasons connected with metabolic control 
and its formal, mathematical analysis (962–966), changes in the 
metabolome are both expected (967) and found (968–971) to be 
amplified relative to those in the transcriptome and proteome. For 
similar reasons, and coupled with evolution’s selection for robust-
ness (972–978) (i.e., homeostasis) in metabolic networks, we do 
not normally expect to find single metabolic biomarkers for a 
complex disease or syndrome. Since our initial metabolomic ana-
lyzes (654), the technology has improved considerably (979–982), 
TAble 7 | Fourteen metabolites contributing to a preeclamptic “signature” (15).
Metabolite Up or down in Pe Average mass (Da) Chemspider identifier
5-hydroxytryptophan Down 220.225 141
Monosaccharide Up Unspecified Unspecified
Decanoylcarnitine Up 315.448 8420677
Methylglutaric and/or adipic acid Down 146.141 11549/191
Oleic acid Up 282.461 393217
Docosahexaenoic acid and/or docosatriynoic acid Up 328.488 393183/absent
γ-Butyrolactone and/or oxolan-3-one (dihydrofuran-3-one) Up 86.089 7029/461367
2-Oxovaleric acid and/or oxo-methylbutanoic acid Up 116.115 67142/absent
Acetoacetic acid Up 102.089 94
Hexadecenoyleicosatetraenoyl-sn-glycerol Up n/a Absent
Di-(octadecadienoyl)-sn-glycerol Up 616.954 4942782
Sphingosine-1-phosphate Up 379.472 4446673
Sphinganine 1-phosphate Up 381.488 559277
Vitamin D3 derivatives Up n/a Unspecified
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a full human metabolic network reconstruction has been pub-
lished (978, 983–985) in the style of that done for yeast (986), 
and a number of candidate metabolomics biomarkers for PE have 
been identified reproducibly on an entirely separate validation 
set (15, 655).
This latter, LC-MS-based, study (15) found a cohort of 14 
metabolites from the first-trimester that when combined gave 
an OR of 23 as being predictive of third-trimester PE. For con-
venience, we list them in Table 7. Note that because they were 
characterized solely via their mass, there are some uncertainties 
in the exact identification in some cases, and that untargeted 
metabolomics of this type has a moderately high limit of detec-
tion (maybe 10 μM) such that many potentially discriminatory 
metabolites are below the limit of detection.
A number of features of interest emerge from this:
 1. All the markers save 5-hydroxytryptophan and adipic/meth-
ylglutaric acid that were raised in PE; 5-hydroxytryptophan 
is a precursor of serotonin [which in some studies (987) has 
been seen to be mildly elevated in PE].
 2. Markers came from multiple classes of metabolite or areas of 
metabolism, including amino acids, carbohydrates, carnitines, 
dicarboxylic acids, fatty acids (especially), (phospho)lipids, 
and sterols.
 3. γ-Butyrolactone derivatives can act as signaling molecules for 
a variety of bacteria (988, 989).
 4. In common with many other inflammatory diseases (145), 
Vitamin D3 levels [usually measured as 25(OH)vitD or cal-
cidiol] are often lower in PE (990–994) [cf. Ref. (995–997)], 
consistent with the levels of their derivatives being raised. 
However, the direction of causality inflammation ←→ vitamin 
D levels is not yet known (998) [see also Ref. (143, 145, 996)].
 5. None of these metabolites was among four metabolites 
proposed as first-trimester biomarkers in two other (smaller) 
studies from different groups (656, 999).
 6. Sphingolipid metabolism can be deranged in PE (1000) [also 
in Parkinson’s (1001)].
As well as the non-targeted metabolomics noted above, a 
number of other small molecule biomarkers have been turned up 
by more conventional measurements.
Noradrenaline (Norepinephrine)
An interesting early study (1002) found that venous plasma 
noradrenaline was raised by 67% in preeclamptics vs. controls. 
Similar data were found by others (1003). This is of particular 
interest in the present context since noradrenaline is well 
established as highly growth stimulatory to Gram-negative 
microorganisms [e.g., Ref. (1004–1008)], in part by acting as a 
siderophore (1009–1011). It also raises the levels of neuropeptide 
Y (820), and as a stress hormone (1012), is of course well known 
for its role in raising BP, a hallmark of PE.
There is relatively little metabolomics work in sepsis, but 
in one study, carnitine and sphingolipid metabolism were also 
modified during sepsis (1013), while in another (1014), a suite 
of molecules were decreased during acute sepsis. However, the 
patients involved here were quite close to death, so it is not clear 
that comparisons between the metabolome in PE and in dying 
patients are that worthwhile.
We also note a recent and rather interesting suggestion by 
Eggers (1015) that the maternal release of adrenaline (rather 
than noradrenaline) may have an important etiological role in PE, 
although as with the rest of our thesis here it is not there indicated 
as to what causes the adrenaline to rise (although infection and 
inflammation can of course do so).
Uric Acid
Hyperuricemia is a moderately common finding in preeclamptic 
pregnancies and may even be involved in its pathogenesis [see, 
e.g., Ref. (1016–1022)]. However, it does not seem to be very 
specific (1023–1027) and is seemingly not an early biomarker 
[and it did not appear in our own study (15)]. Its lack of specific-
ity is illustrated by the fact that there is considerable evidence for 
the roles of purinergic signaling (1028), and especially the role 
of uric acid, in Alzheimer’s and Parkinson’s disease (1029–1031), 
as well as in a variety of other kinds of inflammatory processes, 
including pro-inflammatory cytokine production (1032, 1033), 
the Plasmodium falciparum-induced inflammatory response 
(1034), the mechanistic basis for the action of alum as an 
adjuvant (1035), and even peanut allergy (1036–1038). As is 
common in case–control studies when just one disease (e.g., PE) 
is studied, artificially high levels of sensitivity and (especially) 
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specificity may appear when other patients with other diseases 
are not considered.
ClOTTiNg, COAgUlOPATHieS,  
AND FibRiNOgeN iN Pe
In much of our previous work [e.g., Ref. (126–134)], we have 
noted that each of these chronic, inflammatory diseases is accom-
panied by changes in fibrin fiber morphologies, coagulopathies, 
and changes in erythrocytes that are both substantial and char-
acteristic. They can variously be mimicked by adding unliganded 
iron or LPS. As is well known, LPS itself is a strong inducer of 
coagulation, whether via tissue factor or otherwise [e.g., Ref. 
(1039–1048)], and will bind to fibrin strongly (259, 1049). The 
morphological methods have not yet, to our knowledge, been 
performed on blood from preeclamptics, whether as a diagnostic 
or a prognostic, although we note that clotting factors came top 
in one GWAS looking for gene–PE associations (117). Fibrinogen 
itself is a TLR4 ligand (1050), is raised in PE (1051–1055), and we 
note the extensive evidence for coagulopathies during pregnan-
cies with PE [e.g., Ref. (64, 128, 527, 741, 1056–1068)]. In the 
worst cases, these are the very frightening DIC (1047, 1069–1073) 
that can, of course, also emerge as a consequence of sepsis 
(1074–1080). Variations in the plasminogen activator inhibitor-1 
may contribute to the hypofibrinolysis observed (1081–1083).
We recently showed that LPS can potently induce amyloid 
formation in fibrin (258, 259, 1084, 1085). Thus, in addition, we 
note the increasing recognition that amyloid proteins themselves, 
that may occur as a result of coagulopathies, are themselves both 
inflammatory [e.g., Ref. (565, 669, 1086–1091)] and cytotoxic 
[e.g., Ref. (257, 1092–1096)], and that this can of itself contribute 
strongly to the death of, e.g., trophoblasts.
Related to clotting parameters are three other “old” but easily 
measured variables that probably reflect inflammation (1097), 
that have been suggested to differ in PE from normotensives, and 
may have some predictive power. The first two are the erythrocyte 
sedimentation rate (ESR) (1098, 1099) and the red cell distribution 
width (RDW) (1100) [but cf. Ref. (1101)]. Interestingly, the former 
was the only variable that was predictive of a subsequent stroke 
following sub-arachnoid hemorrhage (1102). The third relates to 
the morphology of erythrocytes (that may in part underpin the 
other two). We and others have shown in a series of studies [e.g., 
Ref. (134–136, 1103–1106)] that erythrocyte morphology diverges 
very considerably from that “classical” discoid shape adopted by 
normal healthy cells, and that this can be a strong indicator of dis-
ease (137). In extreme cases [e.g., Ref. (133, 1107–1112)], including 
following infection (1113), this results in eryptosis, the suicidal 
death of erythrocytes. It is of interest that ceramide, a precursor 
of sphingosine-1-phosphate (S1P) (Table 7), is raised in various 
diseases such as Parkinson’s and may serve to stimulate eryptosis 
(1114). Although we know of no direct measurements to date, there 
is evidence that eryptosis may play a significant role in PE (1115).
PReveNTiON STRATegieS
Apart from low-dose aspirin [that may have little effect 
(1116–1119) unless initiated relatively early in pregnancy 
(1120–1124)], and low-dose calcium (1125), there are relatively 
few treatment options in present use (1126–1129). [Magnesium 
sulfate (1130–1132) has been used as a treatment for eclampsia 
and, interestingly, prevents LPS-induced cell death in an in vitro 
model of the human placenta (1133).]
In the history of science or medicine, some treatments are 
empirical, while others are considered to have a mechanistic 
basis. The general assumption is that the more we know about 
the originating etiology of a disease or syndrome the more likely 
we are to be able to treat its causes effectively, and not just its 
symptoms. Clearly, also, clinicians are rightly loth to give complex 
and potentially teratogenic treatments to pregnant women when 
this can be avoided (1134–1137). However, the surprising lack of 
systematic data with antibiotics (1138), modulo one particularly 
spectacular success (540), suggests that we ought to be perform-
ing trials with safe antibiotics on women at special risk (1139). 
These must take care to avoid any Jarisch–Herxheimer reac-
tion (1140–1143) due to the release from microbes induced by 
antibiotics of inflammagens such as LPS (1144–1147). A related 
strategy recognizes that some FDA-approved drugs can actually 
exert powerful antibiotic effects in vivo (but not on petri plates) 
by modifying the host (1148).
Because of the known oxidative stress accompanying PE, it 
had been assumed that antioxidants such as vitamin C (ascorbate) 
might be preventive; however, this turned out not to be the case 
(even the opposite) for ascorbate (1118, 1149). Probably, this is 
because in the presence of unliganded iron, ascorbate is, in fact, 
pro-oxidant (125). However, polyphenolic antioxidants that actu-
ally act by chelating iron (84, 125) seem to be more effective (1150).
Another area that we and others have previously highlighted 
recognizes the ability of non-siderophoric iron chelators to act as 
iron-withholding agents and thereby limit the growth of bacteria. 
Again, a prediction is that women with iron overload diseases 
should be more susceptible to PE, a prediction that is borne 
out for α-thalassemia (1151, 1152) though not apparently for 
hereditary hemochromatosis (1153). However, the extent of use 
of chelators and degree of control of free iron, thereby obtained 
is rarely recorded in any detail, so in truth it is difficult to draw 
conclusions.
The general benefits of nutritional iron chelators such as blue-
berries and other fruits and vegetables containing anthocyanins 
have been discussed elsewhere [e.g., Ref. (84, 125, 1154)].
How significant coagulopathies are to the etiology of PE 
development (as opposed to providing merely an accompani-
ment) is not entirely clear, but on the basis that they are then 
anticoagulants would potentially assist, just as thrombomodulin 
does in DIC accompanying sepsis (942, 943, 1079, 1080). Of 
course, one of many effects of low-dose aspirin is to act as an 
anticoagulant. There is also evidence for the efficacy of heparin 
(6, 1127, 1155–1160), which is especially interesting given our 
highlighting of the role of coagulopathies in PE. These antico-
agulants that avoid bleeding (1161) are obviously of particular 
interest, while anything stopping the fibrin forming β-amyloid 
(258, 259) should serve as an especially useful anti-inflammatory 
anticoagulant.
With a change in focus from function-first to target-first-based 
drug discovery (976), there has been an assumption that because 
FigURe 8 | Some structures of various statins.
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a drug is (i) found to bind potently to a molecular target and (ii) 
has efficacy at a physiological level in vivo, the first process is thus 
responsible for the second. This has precisely no basis in logic [it 
is a logical fault known variously as “affirming the consequent” 
or “post hoc ergo propter hoc” (1162)]. This is because the drug 
might be acting physiologically by any other means, since drug 
binding to proteins is typically quite promiscuous [e.g., Ref. 
(1163–1167)]. Indeed, the average known number of binding sites 
for marketed drugs is six (208, 1168). In particular, it is likely, 
from a network or systems pharmacology perspective [e.g., Ref. 
(978, 1169–1172)], that successful drugs (like aspirin) are suc-
cessful precisely because they hit multiple targets. The so-called 
“statins” provide a particularly good case in point (125).
It had long been known that the enzyme HMGCoA reductase 
exerted strong control on the biosynthetic flux to cholesterol, and 
that inhibiting it might lower the flux and steady-state cholesterol 
levels (as indeed it does). Notwithstanding that cholesterol alone 
is a poor predictor of cardiovascular disease (1173–1175), espe-
cially in the normal range, HMGCoA reductase inhibitors have 
benefits in terms of decreasing the adverse events of various types 
of cardiovascular disease (1176). Following an original discovery 
of natural products such as compactin (mevastatin) and lovas-
tatin containing a group related to hydroxymethylglutaric acid 
(rather than a CoA version) that inhibited the enzyme (1177), 
many variants with this (hydroxyl)methylglutaric substructure 
came to be produced, with the much larger “rest” of the molecule 
being considerably divergent [see Figure 8, where the MW values 
vary from 390.5 (mevastatin) to 558.6 (atorvastatin)]. Despite 
this wide structural diversity (Figure 8), they are still collectively 
known as “statins,” and despite the wildly illogical assumption 
that they might all work in the same way(s). The fact that different 
statins can cause a variety of distinct expression profiles (1178) 
is anyway utterly inconsistent with a unitary mode of action. 
In particular, in this latter study, statins clustered into whether 
they were (fluvastatin, lovastatin, and simvastatin) or were not 
(atorvastatin, pravastatin, and rosuvastatin) likely to induce the 
side-effect of rhabdomyolysis or any other myopathy. Clearly, 
any choice of “statin” should come from the latter group, with 
pravastatin and rosuvastatin being comparatively hydrophilic.
The epidemiological fact of improved survival despite the 
comparative irrelevance of cholesterol levels to atherosclerotic 
plaque formation and heart disease in the normal range provides 
an apparent paradox (1179). This is easily solved by the recognition 
[e.g., Ref. (1180–1193), and many other references and reviews] 
that “statins” are, in fact, anti-inflammatory. They may also be anti-
microbial/antiseptic, whether directly or otherwise (1194–1198), 
and we also note the role of cholesterol in mopping up endotoxin 
(1199). Finally, here, it needs to be recognized that statins do them-
selves serve to lower iron levels (1200–1202), and (while oddly 
this seems not to have been tested directly) simple inspection of 
their structures (Figure 8) implies that the better ones (with their 
multiple OH groups) might, in fact, chelate iron directly.
In consequence, a number of authors have indicated the 
potential utility of statins in treating PE (113, 545, 1203–1213), 
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and pravastatin has been the subject of a number of favorable 
studies (545, 1204, 1206, 1209, 1211, 1214, 1215), including in 
humans (1204, 1216–1218). Pravastatin seems more than ripe for 
a proper, randomized clinical trial (1203).
Another “vascular” class of drugs that has been proposed for 
treating PE is represented by those of the family of vasodilatory 
phosphodiesterase 5 inhibitors such as sildenafil (Viagra) and 
vardenafil (Levitra), as it is reasonable that they might improve 
endothelial function, especially if started early in pregnancy 
(1219). Thus, vardefanil restores endothelial function by increas-
ing PlGF (1220), and sildenafil has shown promise in a number 
of animal studies (1221–1226) and in human tissues (1227, 1228), 
with a clinical trial ongoing (1229). In particular (1226), it was 
able to normalize the metabolomics changes observed in a mouse 
model (the COMT−/− model) of PE.
Anti-hypertensive therapy for PE has been reviewed by 
Abalos and colleagues (1230) and Magee and colleagues (114). 
Anti-hypertensives did halve the incidence of hypertension but 
had no effect on PE. Methyldopa is one of the most commonly 
used anti-hypertensives in pregnancy, but it may also stimulate 
eryptosis (1231); alternative drugs were considered to be better 
(1230) for hypertension. Nifedipine (1232) and labetalol (1233) 
are considered a reasonable choice. There was also a slight 
reduction in the overall risk of developing proteinuria/PE when 
beta blockers and calcium channel blockers considered together 
(but not alone) were compared with methyldopa (1230). In 
mice, olmesartan (together with captopril) proved usefully anti-
hypertensive (1234); this is of interest because olmesartan is also 
an agonist of the vitamin D receptor (1235). However, it was not 
mentioned in either Ref. (1230) or Ref. (114).
Lipopolysaccharide itself has long been recognized as a target 
of inflammatory diseases. Unfortunately, despite initially prom-
ising trials of an anti-LPS antibody known as centoxin (1236), it 
was eventually withdrawn, apparently because of a combination 
of ineffectiveness (1237, 1238) and toxicity (1239, 1240). LPS is 
rather hydrophobic, and thus it is hard to make even monoclonal 
antibodies very selective for such targets, such that the toxicity 
was probably because of its lack of specificity between lipid A 
and other hydrophobic ligands (1241). Other possible treat-
ments based on LPS, such as “sushi peptides” (1242–1249) [or 
variants (1250, 1251)], and LPS-binding protein were covered 
elsewhere (140).
If an aberrant or dysbiotic gut microbiome is the source of 
the microbes that underpin PE, it is at least plausible that the gut 
microbiome should be predictive of PE (378), but we know of no 
suitably powered study that has been done to assess this, and this 
would clearly be worthwhile. However, in a study of primiparous 
women, the OR for getting severe PE was only 0.6 if probiotic 
milk drinks containing lactobacilli were consumed daily (1252). 
This is a very significant effects, such that this too seems an area 
well worth following up.
From a metabolomics point of view, the molecules seen to be 
raised in PE may either be biomarkers of the disease etiology or 
of the body’s attempts to respond to the disease [and this is true 
generally (1253)]. Thus, it is of great interest that S1P was raised in 
PE [see Kenny (15) and Table 7]. S1P is mainly vasoconstrictive 
(1254, 1255), but agonists of the S1P-1 receptor (that is involved 
in endothelial cell function) seemed to have considerable value 
in combatting the cytokine storm that followed infection-driven 
sepsis (1256–1261). The detailed mechanism seems not to be 
known, but in the context of infection, a need for S1P and other 
sphingolipids for successful pregnancies (1262, 1263) [see also 
Parkinson’s (1001)], and the induction of PE by its disruption 
(1000, 1264–1268), some serious investigation of the potential 
protective effects of S1PR1 agonists seems highly warranted.
Among other small molecules, melatonin has shown some 
promise in the treatment of septic shock, by lowering inflam-
matory cytokine production (1269) [and see Gitto et al. (1270) 
for neonatal oxidative stress], and a trial is in prospect for PE 
(1271).
Lipoxin A4 (LXA4) is considered to be an endogenous stop 
signal in inflammation. While recognizing the difficulties with 
rodent PE models (above), we note that in one study, the effect of 
BML-111 (a synthetic analog of LXA4) was tested on experimen-
tal PE induced in rats by low-dose endotoxin (LPS), and showed 
highly beneficial effects (549).
CODA – A ReTURN TO THe bRADFORD 
Hill CRiTeRiA
Returning to the Bradford Hill criteria for ascribing causation of a 
disease to an environmental factor (97), we can now ask whether 
a detectable (if largely dormant) microbiome X, that is more likely 
to replicate with free iron, and that can anyway secrete or shed a 
variety of inflammatory components such as LPS, represents a 
plausible and major etiological factor for PE (Y):
(1) what is the strength of association between X and Y? We 
found an overwhelming co-occurrence of microbes or their 
products and PE.
(2) what is the consistency of association between X and Y? 
Almost wherever we looked, whether via periodontal disease 
(PD), UTI, or other means of ingress, we could find a micro-
bial component in PE.
(3) what is the specificity of association between X and Y? 
Insufficient data are available to ascribe PE solely to one type of 
organism; however, these data clearly indicate that a variety of 
microbes, each capable of shedding inflammatory molecules 
such as LPS, can serve to stimulate or exacerbate PE.
(4) experiments verify the relationship between X and Y. It is 
unethical to do these in humans in terms of purposely infecting 
pregnant women, but data from antibiotics show the expected 
improvements.
(5) modification of X alters the occurrence of Y; this is really 
as (4).
(6) biologically plausible cause and effect relationship. Yes, this is 
where we think the ideas set down here are entirely consistent 
with current thinking on the main causes of PE. What we 
add in particular is the recognition that bacteria (and other 
microbes) that may be invisible to culture are both present 
and responsible, by established means, for the inflammation 
and other sequelae (and especially the coagulopathies) seen 
as causative accompaniments to PE.
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OTHeR PReDiCTiONS
Classical clinical microbiology, involving mainly replication-
based methods, is evolving rapidly to assess the microbial 
content of samples on the basis of DNA sequences (296, 1272), 
including 16S rDNA (287, 288, 290, 292, 293, 295, 297, 1273), 
suitable protein-encoding housekeeping genes [e.g., Ref. 
(1274–1279)], and, increasingly, full genome sequences (1280). 
In the future, we can thus expect a considerable increase in 
molecular assessments of the microbiological content of blood, 
urine, and tissues, and this will obviously be a vital part of 
the experimental assessment and development of the ideas 
presented here. Molecular methods will also be used to assess 
maternal circulating DNA (1281–1283) and RNA (1284) in 
terms of both its presence and sequencing, as well as the use of 
digital PCR (1285).
Since PE has such a strong vascular component, we also pre-
dict that measurements designed to detect coagulopathies will 
increase in importance, for both diagnosis and prognosis, and for 
assessing treatments.
New drugs designed to kill non-growing bacteria (1286–1290) 
or to overcome amyloid coagulopathies (1291–1295) will be 
needed and will come to the fore.
Finally, we consider that real progress in understanding PE 
from a systems biology perspective means that it must be mod-
eled accordingly, and this must be a major goal.
CONClUDiNg ReMARKS
We have brought together a large and widely dispersed literature 
to make the case that an important etiological role in PE is played 
by dormant microbes, or at least ones that are somewhat refrac-
tory to culture, and that these can awaken, shed inflammagens 
such as LPS, and thereby initiate inflammatory cascades. (The 
sequelae of these, involving cytokines, coagulopathies, and so 
on, are well enough accepted.) The case is founded on a large 
substructure of interlocking evidence, but readers might find the 
following elements as discussed above, especially persuasive and/
or worthy of follow-up:
•	 the regular presence of detectable microbes in preeclamptic 
placentas [e.g., Ref. (400, 426, 427)].
•	 the fact that endotoxin (LPS) can act as such a mimic for 
invoking PE in experimental models.
•	 the fact that every known proteomic biomarker suggested for 
PE has also been shown to increase during infection.
•	 the significant number of papers reviewing a link between 
infection and PE [e.g., Ref. (53, 54, 138, 371)].
•	 the almost complete absence (one case) of PE in patients 
treated with spiramycin (540).
Any and all of these provide powerful strategies for testing 
whether PE is, in fact, such as gastric ulcers (166, 168, 169, 1296), 
essentially initiated as an infectious disease.
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